The Market Got What It Wanted. So Why Did Nobody Care?
Here’s what it means when a rate-friendly session fails to attract buying. Plus, Dick’s results raise a familiar question..
Investors Are Rotating into Defensive Positions as Market Conditions Deteriorate
These names carried the market on Friday as a choppy decline looms ahead.
After Moderna’s Big News, Here Are Three Biotechs to Watch
I’m following these lesser-known names amid biopharma’s move on Wednesday.
The Market Is a Mess — And the Indexes Are Hiding the Truth
The indexes are terrible timing devices, and this week proves it.
Moderna Leads the Charge as Pharma ETF Hits All-Time High
Tempus AI and Merck are key contributors to Moderna’s success.
2 Significant Positive Events Aren’t Enough to Fix the Market
A Treasury intervention and 170% move in Moderna produced only a 0.2% gain in the S&P 500.
Scott Bessent’s Surprise Bond Move Helped, But Moderna Does the Heavy Lifting
The indices held up on one biotech breakthrough while the Nasdaq lost ground.
Retail Loses Interest in Overbought Market, and the Question Is Why
The investors who have been correct lately are not enthusiastic as the market is overbought and complacent.
Back to Work With a Key Market Level You Should Be Watching
It’s a choppy market that can slice, dice, and chop your portfolio. Here’s what I’m paying attention to.
When Will the Nasdaq Be Oversold?
Let’s answer a reader’s important question today about the Nasdaq.